Skip to main content

Table 1 Subjects' clinical characteristics at baseline.

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

  Placebo
(25)
Raloxifene
(50)
Tamoxifen
(50)
Age
(Lower-upper quartile)
44
(42-47)
46
(42-49)
45
(41-49)
Age at menarche
(Lower-upper quartile)
13
(12-13)
12
(12-13)
12
(11-14)
Parity 1 2 2
Family history1
BC°- OC°°
5 - 1 15 - 1 11 - 3
Body mass index
(Lower-upper quartile)
22.9
(21.7-26.2)
22.2
(20.5-24.6)
22.2
(20.3-25.2)
Smoking
Never/former/current/
missing
14/3/8/0 28/10/11/1 24/5/21/0
Tumor size mm
(Lower-upper quartile)
22.0 (15-30) 22.5 (15.0-28.5) 21.5 (15.0-27.5)
Tumor grade
1/2/3/unknown2
7/7/5/6 3/23/7/17 3/22/8/17
HER2 overexpression %
No/yes
96/4 98/2 94/6
Luminal subtype %
A/B HER2 neg/B HER2 pos
36/60/4 20/78/2 27/67/3
  1. 1First or second degree relatives with °breast cancer (BC) or °°ovarian cancer (OC); 2not graded by the pathologist.